Skip to content

Author

T. Kebdani

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access 2026

Artificial Intelligence in Radiation Oncology: Current applications, clinical impact, and future perspectives. A Narrative Review

Radiation oncology is a highly digital and data-intensive discipline in which artificial intelligence (AI) is increasingly being incorporated into the clinical workflow. From image analysis and automatic segmentation to treatment planning, adaptive radiotherapy, radiomics, and outcome prediction, AI has the potential to improve efficiency, reproducibility, and treatment personalization. This narrative review summarizes the principal concepts underlying machine learning and deep learning and examines their current applications across the radiation therapy pathway. Particular attention is given to automated contouring, knowledge-based and automated planning, cone-beam computed tomography (CBCT)- and magnetic resonance imaging (MRI)-guided adaptive radiotherapy, toxicity and tumor-control prediction, and the integration of radiomic, clinical, dosimetric, and molecular data. The available literature suggests that AI can reduce repetitive workload and inter-observer variability and may facilitate more consistent treatment planning. However, technical performance alone does not establish clinical benefit. Major challenges include data quality, dataset bias, limited external generalizability, interpretability, cybersecurity and data governance, and the need to define responsibility when AI-generated outputs are used in patient care. Prospective, multicenter validation and continuous quality assurance are therefore essential. The future of AI in radiation oncology is unlikely to be the replacement of the radiation oncologist, but rather a human–AI partnership in which automation supports clinical expertise. If AI successfully releases clinical time, this resource should be reinvested in patient communication, shared decision-making, research, innovation, and education.

S. Ichou, K. Nouni, A. Lachgar et al. · 0 citations
Open access Aug 2026

Tumor Stage as A Determinant of Treatment-Related Toxicity in Laryngeal Cancer: A Retrospective Cohort Study at the National Institute of Oncology, Rabat

Background: Laryngeal cancer is one of the most common malignancies of the upper aerodigestive tract. Its management relies on surgery, radiotherapy, chemotherapy, or combined treatment modalities according to tumor stage. Although current therapeutic strategies have improved locoregional control and organ preservation, treatment-related toxicity remains a major clinical concern, particularly among patients with locally advanced disease. This study aimed to evaluate the association between tumor stage and treatment-related toxicity in patients treated for laryngeal cancer at the National Institute of Oncology in Rabat. Methods: We conducted a retrospective cohort study including patients with histologically confirmed laryngeal cancer treated at the Department of Radiation Oncology of the National Institute of Oncology, Rabat, between January 2022 and January 2024. Clinical, tumor-related, treatment-related, and toxicity data were collected from medical records. Tumor stage was determined according to the TNM classification, and patients were categorized into two groups: early-stage disease and locally advanced disease. Acute and late toxicities were assessed using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. The association between tumor stage and treatment-related toxicity was analyzed using comparative statistical tests. Results: A total of 127 patients were included. The median age was 56 years, with a marked male predominance. Most patients presented with locally advanced disease at diagnosis.

F. Chakib, I. Lahlou, A. Lachgar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.